The Pharma Data

NOVEMBER 5, 2020

For the first time, the world has rallied behind a plan to accelerate the development of the vaccines, diagnostics and therapeutics we need, and to ensure they are available to all countries on the basis of equity. The Access to COVID-19 Tools (ACT) Accelerator is delivering real results. The WHA will consider a draft resolution ( EB146.R10

International 52

International Compliance Virus Vaccine 52

The Pharma Data

NOVEMBER 16, 2020

This higher risk is manifested throughout the lifecycle starting with an increased risk of acquiring human papilloma virus infection (HPV), more. HPV vaccination, screening and treatment for cervical pre-cancer and cancer, which are critical to preventing and managing cervical cancer are yet to be fully scaled up, contributing.

Vaccine 52

Vaccine Treatment Virus 52

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  A study from Oxford University demonstrated that in 2019, 1.27 million deaths were directly attributable to antibiotic resistance, with another 4.95 million deaths associated with it. The World Bank' s projection of a potential $3.4

Pharmaceutical Companies 71

Pharmaceutical Companies Government Pharmaceuticals DNA 71

PerkinElmer

JANUARY 25, 2023

Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more. With the expanding territory of I.

Science 52

Science Laboratories Immune Response Disease 52

The Pharma Data

MAY 4, 2021

” “Even as the world makes progress on vaccine roll-outs, it remains vital for treatments to be available that can make a meaningful difference for those fighting COVID-19,” said David A. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. Polio/Pertussis/Hib vaccines (incl. Influenza vaccines (incl. Meningitis/Pneumo vaccines (incl.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. Speeding up sales growth. Sales growth at Bayer is planned to regain momentum in 2021 and further accelerate in the years thereafter.

Science 52

Science Pharmaceuticals Licensing Licensing 52